Strengths
- $1.7B Series C valuation and private issuer status are publicly supported.
- Company reports rapid covered-life growth to >25M.
- Public outcomes releases support clinical/ROI signals but need validation.
Diligence report
Pomelo Care
Pomelo Care Startup Diligence Research Report
Pomelo could be a scaled value-based women and children healthcare platform if covered lives convert into durable revenue and validated medical-cost savings. The $1.7B valuation is risky without audited financials, cap table, customer-level ROI, and renewal data.
Company profile
Pomelo Care Startup Diligence Research Report
Pomelo Care appears eligible as a private U.S. unicorn based on SEC private issuer data and company-announced January 2026 Series C valuation. The public thesis is strong growth in covered lives plus reported maternity outcomes, but core underwriting depends on private financials, customer contracts, outcome reproducibility, and healthcare compliance.
- Website
- www.pomelocare.com
- Sector
- Virtual women, maternity, pediatric, and value-based healthcare
- Geography
- United States / New York; Delaware issuer in SEC filing
- Stage
- Private unicorn / late-stage venture-backed startup
- Known aliases
- Pomelo Care, Inc., Pomelo
- Report version
- 1.0
- Timezone
- America/New_York
Executive summary
Risks
- Financial opacity and valuation bridge.
- Customer concentration, renewal, and engagement conversion.
- Healthcare regulatory, privacy, clinical, and licensure exposure.
Gaps
- Audited financials, ARR, margins, cash, burn, runway, cap table.
- Pricing, utilization, protocols, platform architecture, model validation.
- Revenue by customer, active use, renewals, churn, top-customer contracts.
- Win/loss, pricing benchmark, market share.
Risk register
R-001: Financial opacity and valuation bridge
Audited financials, ARR, margin, burn, cap table, and round terms are private.
Diligence request: Request audited financials, cap table, financing docs, debt, and valuation bridge.
R-002: Customer concentration and engagement conversion
Covered lives and named customers are public, but revenue concentration, active use, renewal, and churn are private.
Diligence request: Request customer concentration, contracts, utilization, renewals, and references.
R-003: Healthcare regulatory, privacy, clinical, and licensure risk
Multi-state virtual care and health data create HIPAA, telehealth, licensure, credentialing, malpractice, and clinical-quality exposure.
Diligence request: Request compliance policies, SOC 2/HIPAA evidence, BAAs, incident history, malpractice coverage, and licensure matrix.
R-005: Outcome and ROI reproducibility
Outcome claims need full methodology, cohort, confidence interval, and customer-level claims-cost validation.
Diligence request: Request full studies, raw/blinded claims data, and customer ROI files.
R-006: Competitive overlap and pricing pressure
Maven and hybrid clinics overlap as Pomelo expands lifecycle breadth.
Diligence request: Request win/loss analysis, pricing benchmark, and pipeline by competitor.
R-004: Expansion execution beyond maternity
Expansion into broader women and children categories increases product, clinical, and GTM complexity.
Diligence request: Review roadmap, pilots, budgets, clinical validation, and go/no-go milestones.
R-007: Hiring, retention, and management depth
Public hiring suggests scaling needs; turnover, compensation, and management depth are private.
Diligence request: Request org chart, headcount plan, compensation, equity, attrition, and references.
R-008: Legal, IP, and regulatory completeness
Trademark evidence is public, but litigation, regulatory, insurance, contracts, and IP ownership require counsel diligence.
Diligence request: Request legal schedule, docket searches, regulatory correspondence, insurance, contracts, IP assignments, and open-source scan.
01Financial Information
Public sources verify financings and latest valuation; core financial quality remains private.
I.A Annual and quarterly financial information for the past three years
not publicly verifiable confidence: low
Annual and quarterly financial information for the past three years: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for annual and quarterly financial information for the past three years records and management explanation.
Hidden risks
- Public sources may omit material annual and quarterly financial information for the past three years risks.
Follow-up questions
- Provide supporting documents for annual and quarterly financial information for the past three years and reconcile to public claims.
I.B Financial Projections
partially verified confidence: medium
Financial Projections: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for financial projections records and management explanation.
Hidden risks
- Public sources may omit material financial projections risks.
Follow-up questions
- Provide supporting documents for financial projections and reconcile to public claims.
I.C Capital Structure
partially verified confidence: medium
Capital Structure: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for capital structure records and management explanation.
Hidden risks
- Public sources may omit material capital structure risks.
Follow-up questions
- Provide supporting documents for capital structure and reconcile to public claims.
| stakeholder | public position | diligence caveat | status |
|---|---|---|---|
| Common/employee holders | not disclosed | need fully diluted cap table | not_publicly_verifiable |
| Named venture investors | First Round, a16z, Stripes, BoxGroup, SV Angel, others | ownership and preferences private | partially_verified |
| Debt/warrants/notes | not disclosed | need debt and dilutive securities schedule | not_publicly_verifiable |
I.D Other financial information
partially verified confidence: medium
Other financial information: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for other financial information records and management explanation.
Hidden risks
- Public sources may omit material other financial information risks.
Follow-up questions
- Provide supporting documents for other financial information and reconcile to public claims.
| date | event | amount | valuation | status |
|---|---|---|---|---|
| 2021-06-18/2021-08-25 | SEC Form D | $7.96M sold | not disclosed | verified |
| 2024-06-20 | Series B | $46M | not disclosed; total funding $79M | verified |
| 2026-01-08 | Series C | $92M | $1.7B | verified |
02Products
Public pages describe virtual multi-specialty care, outcome claims, and predictive workflows; pricing and technology maturity remain private.
II.A Description of each product
partially verified confidence: medium
Description of each product: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for description of each product records and management explanation.
Hidden risks
- Public sources may omit material description of each product risks.
Follow-up questions
- Provide supporting documents for description of each product and reconcile to public claims.
| product | audience | evidence | status |
|---|---|---|---|
| Virtual maternity and infant care | payor/employer members | 24/7 team, personalized plans, remote monitoring | partially_verified |
| Population health programs | health plans | preeclampsia, diabetes, behavioral health, NICU family care | partially_verified |
| Women/children expansion | broader lifecycle | reproductive care, pediatrics, midlife, condition management | partially_verified |
| item | public signal | gap | status |
|---|---|---|---|
| Customer ROI | 3-5x ROI / 2.3:1 Medicaid ROI claims | need contract-specific methods | partially_verified |
| Contract pricing | not disclosed | need PMPM/case/value-based fees | not_publicly_verifiable |
| Product gross margin | not disclosed | need service delivery cost and clinician ratios | not_publicly_verifiable |
Public materials describe product components but not internal implementation, clinical protocols, or model validation.
03Customer Information
Named customers/partners and covered-life claims support traction, but revenue concentration and renewals are private.
III.A Top customers by application
partially verified confidence: medium
Top customers by application: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for top customers by application records and management explanation.
Hidden risks
- Public sources may omit material top customers by application risks.
Follow-up questions
- Provide supporting documents for top customers by application and reconcile to public claims.
| customer | segment | public evidence | status |
|---|---|---|---|
| Penn Medicine | employer/provider | named in June 2024 release | partially_verified |
| Koch Industries | employer | named in June 2024 release | partially_verified |
| Elevance-affiliated plans in TX/TN/KY/GA | health plans | named in June 2024 release | partially_verified |
| Other leading plans/employers | payor/employer | >25M covered lives claim | partially_verified |
III.B Strategic relationships
partially verified confidence: medium
Strategic relationships: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for strategic relationships records and management explanation.
Hidden risks
- Public sources may omit material strategic relationships risks.
Follow-up questions
- Provide supporting documents for strategic relationships and reconcile to public claims.
| relationship | nature | evidence | gap |
|---|---|---|---|
| Health plans | customer/distribution | commercial and Medicaid plan partnerships | economics and renewal terms |
| Employers | benefits channel | employer marketing page | pricing and broker channel |
| The Doula Network | acquired in-person doula support | 2024 acquisition release | integration and retention |
| Cloud/telehealth/data vendors | critical suppliers | platform uses data and virtual channels | supplier names, SLAs, security |
III.C Revenue by customer
not publicly verifiable confidence: low
Revenue by customer: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for revenue by customer records and management explanation.
Hidden risks
- Public sources may omit material revenue by customer risks.
Follow-up questions
- Provide supporting documents for revenue by customer and reconcile to public claims.
III.D Significant relationships severed within the last two years
not publicly verifiable confidence: low
Significant relationships severed within the last two years: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for significant relationships severed within the last two years records and management explanation.
Hidden risks
- Public sources may omit material significant relationships severed within the last two years risks.
Follow-up questions
- Provide supporting documents for significant relationships severed within the last two years and reconcile to public claims.
III.E Top suppliers
not publicly verifiable confidence: low
Top suppliers: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for top suppliers records and management explanation.
Hidden risks
- Public sources may omit material top suppliers risks.
Follow-up questions
- Provide supporting documents for top suppliers and reconcile to public claims.
04Competition
Pomelo faces virtual and hybrid women/family health competitors, especially Maven as a scaled comparator.
IV.A Competitive landscape by market segment
partially verified confidence: medium
Competitive landscape by market segment: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for competitive landscape by market segment records and management explanation.
Hidden risks
- Public sources may omit material competitive landscape by market segment risks.
Follow-up questions
- Provide supporting documents for competitive landscape by market segment and reconcile to public claims.
| company | segment | scale | overlap |
|---|---|---|---|
| Pomelo Care | virtual maternity/women children care | $1.7B valuation; >25M covered lives | target |
| Maven Clinic | virtual women/family benefits | $125M Series F; >2,000 clients | fertility, maternity, parenting, menopause |
| Oula | maternity/women clinics | NYC/CT positioning | maternity/gynecology |
| Millie | Bay Area maternity/gynecology | local clinic positioning | maternity/gynecology |
| Tia | women health hybrid clinic | in-person and virtual appointments | women/midlife care |
| axis | pomelo position | competitor signal | question |
|---|---|---|---|
| Clinical outcomes | public reductions in preterm/NICU/ED/cost | variable public outcome depth | validate external replication |
| Enterprise scale | >25M covered lives | Maven >2,000 clients | compare active users and revenue |
| Product breadth | expanding beyond maternity | Maven/Tia broad lifecycle | assess differentiation and pricing |
05Marketing, Sales, and Distribution
GTM targets payors and employers with outcome/ROI messaging; productivity and CAC are private.
V.A Strategy and implementation
partially verified confidence: medium
Strategy and implementation: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for strategy and implementation records and management explanation.
Hidden risks
- Public sources may omit material strategy and implementation risks.
Follow-up questions
- Provide supporting documents for strategy and implementation and reconcile to public claims.
| channel | evidence | motion | gap |
|---|---|---|---|
| Health plans | dedicated page and named plan affiliates | enterprise payor/value-based sale | pipeline and economics |
| Employers | employer page and named employers | benefits sale | broker/direct mix |
| Medicaid/labor-trust | Medicaid outcomes and hiring roles | specialized payor/channel sales | state cycles and quotas |
V.B Major Customers
not publicly verifiable confidence: low
Major Customers: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for major customers records and management explanation.
Hidden risks
- Public sources may omit material major customers risks.
Follow-up questions
- Provide supporting documents for major customers and reconcile to public claims.
V.C Principal avenues for generating new business
not publicly verifiable confidence: low
Principal avenues for generating new business: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for principal avenues for generating new business records and management explanation.
Hidden risks
- Public sources may omit material principal avenues for generating new business risks.
Follow-up questions
- Provide supporting documents for principal avenues for generating new business and reconcile to public claims.
V.D Sales force productivity model
partially verified confidence: medium
Sales force productivity model: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for sales force productivity model records and management explanation.
Hidden risks
- Public sources may omit material sales force productivity model risks.
Follow-up questions
- Provide supporting documents for sales force productivity model and reconcile to public claims.
| metric | public signal | required private data | status |
|---|---|---|---|
| Quota capacity | commercial roles listed | quota, ramp, attainment | not_publicly_verifiable |
| CAC/payback | not disclosed | marketing spend, bookings, payback | not_publicly_verifiable |
| Pipeline quality | not disclosed | CRM by stage/channel | not_publicly_verifiable |
V.E Ability to implement marketing plan with current and projected budgets
not publicly verifiable confidence: low
Ability to implement marketing plan with current and projected budgets: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for ability to implement marketing plan with current and projected budgets records and management explanation.
Hidden risks
- Public sources may omit material ability to implement marketing plan with current and projected budgets risks.
Follow-up questions
- Provide supporting documents for ability to implement marketing plan with current and projected budgets and reconcile to public claims.
06Research and Development
R&D centers on clinical pathways, predictive analytics, outcomes research, and expansion beyond maternity.
VI.A Description of R&D organization
partially verified confidence: medium
Description of R&D organization: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for description of r&d organization records and management explanation.
Hidden risks
- Public sources may omit material description of r&d organization risks.
Follow-up questions
- Provide supporting documents for description of r&d organization and reconcile to public claims.
| person or role | role | signal | status |
|---|---|---|---|
| Isabelle Von Kohorn MD PhD | Chief Medical Officer | former neonatology/NICU leadership | verified |
| Staff Software Engineer, Patient Experience | open engineering role | patient experience product build | partially_verified |
| Senior Product Security Engineer | open security role | security capability need | partially_verified |
VI.B New Product Pipeline
partially verified confidence: medium
New Product Pipeline: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for new product pipeline records and management explanation.
Hidden risks
- Public sources may omit material new product pipeline risks.
Follow-up questions
- Provide supporting documents for new product pipeline and reconcile to public claims.
| project | status | timing | risk |
|---|---|---|---|
| Beyond-maternity lifecycle platform | announced use of Series C proceeds | not disclosed | execution complexity |
| Predictive analytics platform | described as existing foundation | current maturity unknown | model validation and bias |
| Outcomes research | ACOG/PRNewswire/public studies | ongoing | replication and claims data |
07Management and Personnel
Founder/CEO and promoted executives are public; headcount, compensation, and turnover are not.
VII.A Organization Chart
partially verified confidence: medium
Organization Chart: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for organization chart records and management explanation.
Hidden risks
- Public sources may omit material organization chart risks.
Follow-up questions
- Provide supporting documents for organization chart and reconcile to public claims.
| name | role | tenure signal | background |
|---|---|---|---|
| Marta Bralic Kerns | Founder & CEO | founder; company founded 2021 | not fully diligenced |
| Shyamali Choudhury | Chief Commercial Officer | joined July 2021 | Flatiron, Brookings, Results for Development |
| Sarah Kramarz | Chief Operating Officer | started January 2022 | Bain and Flatiron |
| Isabelle Von Kohorn MD PhD | Chief Medical Officer | began April 2021 | neonatology/NICU leadership |
VII.B Historical and projected headcount by function and location
partially verified confidence: medium
Historical and projected headcount by function and location: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for historical and projected headcount by function and location records and management explanation.
Hidden risks
- Public sources may omit material historical and projected headcount by function and location risks.
Follow-up questions
- Provide supporting documents for historical and projected headcount by function and location and reconcile to public claims.
| area | public signal | diligence need |
|---|---|---|
| Commercial hiring | payer, Medicaid, partnerships roles | headcount, quotas, ramp |
| Engineering/security hiring | SWE and security roles | roadmap and security capacity |
| Comp/equity/turnover | not disclosed | comp schedule, option ledger, attrition |
VII.C Senior management biographies
not publicly verifiable confidence: low
Senior management biographies: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for senior management biographies records and management explanation.
Hidden risks
- Public sources may omit material senior management biographies risks.
Follow-up questions
- Provide supporting documents for senior management biographies and reconcile to public claims.
VII.D Compensation arrangements
not publicly verifiable confidence: low
Compensation arrangements: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for compensation arrangements records and management explanation.
Hidden risks
- Public sources may omit material compensation arrangements risks.
Follow-up questions
- Provide supporting documents for compensation arrangements and reconcile to public claims.
VII.E Incentive stock plans
not publicly verifiable confidence: low
Incentive stock plans: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for incentive stock plans records and management explanation.
Hidden risks
- Public sources may omit material incentive stock plans risks.
Follow-up questions
- Provide supporting documents for incentive stock plans and reconcile to public claims.
VII.F Significant employee relations problems, past or present
not publicly verifiable confidence: low
Significant employee relations problems, past or present: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for significant employee relations problems, past or present records and management explanation.
Hidden risks
- Public sources may omit material significant employee relations problems, past or present risks.
Follow-up questions
- Provide supporting documents for significant employee relations problems, past or present and reconcile to public claims.
VII.G Personnel Turnover
not publicly verifiable confidence: low
Personnel Turnover: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for personnel turnover records and management explanation.
Hidden risks
- Public sources may omit material personnel turnover risks.
Follow-up questions
- Provide supporting documents for personnel turnover and reconcile to public claims.
08Legal and Related Matters
Trademark and SEC records are public; full legal/regulatory/contract/insurance diligence requires counsel.
VIII.A Pending lawsuits against the Company
inconclusive confidence: low
Pending lawsuits against the Company: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for pending lawsuits against the company records and management explanation.
Hidden risks
- Public sources may omit material pending lawsuits against the company risks.
Follow-up questions
- Provide supporting documents for pending lawsuits against the company and reconcile to public claims.
| matter | public status | status | diligence request |
|---|---|---|---|
| Lawsuits against company | no confirmed matter found | inconclusive | counsel docket search |
| Company-initiated lawsuits | no confirmed matter found | inconclusive | legal matters schedule |
| Regulatory enforcement | no confirmed matter found | inconclusive | agency/counsel checks |
VIII.B Pending lawsuits initiated by Company
inconclusive confidence: low
Pending lawsuits initiated by Company: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for pending lawsuits initiated by company records and management explanation.
Hidden risks
- Public sources may omit material pending lawsuits initiated by company risks.
Follow-up questions
- Provide supporting documents for pending lawsuits initiated by company and reconcile to public claims.
VIII.C Environmental and employee safety issues and liabilities
not publicly verifiable confidence: low
Environmental and employee safety issues and liabilities: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for environmental and employee safety issues and liabilities records and management explanation.
Hidden risks
- Public sources may omit material environmental and employee safety issues and liabilities risks.
Follow-up questions
- Provide supporting documents for environmental and employee safety issues and liabilities and reconcile to public claims.
VIII.D Material patents, copyrights, licenses, and trademarks
partially verified confidence: medium
Material patents, copyrights, licenses, and trademarks: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for material patents, copyrights, licenses, and trademarks records and management explanation.
Hidden risks
- Public sources may omit material material patents, copyrights, licenses, and trademarks risks.
Follow-up questions
- Provide supporting documents for material patents, copyrights, licenses, and trademarks and reconcile to public claims.
| area | public status | source or gap |
|---|---|---|
| POMELO CARE trademark | serial 98635956; Class 044; filed 2024-07-07 | verify USPTO directly |
| Patents/software/data rights | not publicly verified | IP assignments and open-source scan |
| Insurance/material contracts | not public | policies, MSAs, BAAs, acquisition docs |
VIII.E Insurance coverage and material exposures
not publicly verifiable confidence: low
Insurance coverage and material exposures: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for insurance coverage and material exposures records and management explanation.
Hidden risks
- Public sources may omit material insurance coverage and material exposures risks.
Follow-up questions
- Provide supporting documents for insurance coverage and material exposures and reconcile to public claims.
VIII.F Material contracts
not publicly verifiable confidence: low
Material contracts: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for material contracts records and management explanation.
Hidden risks
- Public sources may omit material material contracts risks.
Follow-up questions
- Provide supporting documents for material contracts and reconcile to public claims.
VIII.G Regulatory agency problems
inconclusive confidence: low
Regulatory agency problems: public research provides findings where sources exist; private data-room evidence remains required for checklist completeness.
Evidence gaps
- Private diligence needed for regulatory agency problems records and management explanation.
Hidden risks
- Public sources may omit material regulatory agency problems risks.
Follow-up questions
- Provide supporting documents for regulatory agency problems and reconcile to public claims.
Evidence
| ID | Claim | Status | Sources |
|---|---|---|---|
| EC-001 | Pomelo Care appears private and eligible: SEC shows Pomelo Care, Inc. with no tickers/exchanges and a Form D, and no public IPO/acquisition/shutdown signal was confirmed. | verified high | SRC-003 |
| EC-002 | Pomelo announced a $92M Series C at a $1.7B valuation on Jan. 8, 2026. | verified high | SRC-002 |
| EC-003 | Public financing history includes a 2021 $7.96M Form D and a 2024 $46M Series B bringing total funding to $79M. | verified high | SRC-003SRC-004 |
| EC-004 | Pomelo claims growth from over 3M covered lives in 2024 to more than 25M lives and nearly 7% of U.S. births in 2026. | partially verified medium | SRC-002SRC-004 |
| EC-005 | Pomelo publicly names Penn Medicine, Koch Industries, and Elevance-affiliated plans as customers/relationships. | partially verified medium | SRC-004 |
| EC-006 | Pomelo outcome materials report reductions in preterm births, NICU admissions/stay length, ED use, cost, and improved depression follow-up. | partially verified medium | SRC-005SRC-007 |
| EC-007 | Pomelo describes 24/7 virtual care from a multi-specialty team and an intelligent platform using claims/EHR data and predictive analytics. | partially verified medium | SRC-002SRC-008 |
| EC-008 | Pomelo plans expansion beyond maternity into reproductive care, pediatrics, hormonal health, menopause, preventive care, and condition management. | partially verified medium | SRC-002 |
| EC-009 | Careers postings indicate hiring in payer/labor/Medicaid partnerships, growth, operations, product security, and patient-experience engineering. | verified medium | SRC-009 |
| EC-010 | Pomelo announced Marta Bralic Kerns as Founder & CEO and promotions for Choudhury, Kramarz, and Von Kohorn. | verified high | SRC-010 |
| EC-011 | Maven Clinic is a major competitor/comparator with $125M Series F, over $425M total funding, and >2,000 clients in 175 countries. | verified high | SRC-011 |
| EC-012 | Oula, Millie, and Tia publicly market adjacent maternity/women health clinic or hybrid care models. | verified medium | SRC-012SRC-013SRC-014 |
| EC-013 | A POMELO CARE trademark application, serial 98635956, Class 044, was filed July 7, 2024. | partially verified medium | SRC-015 |
| EC-014 | No confirmed pending lawsuit or regulatory enforcement action was found in reviewed public searches; this is inconclusive. | inconclusive low | SRC-016 |
| EC-015 | Pomelo acquired The Doula Network in 2024 to add in-person doula support to virtual maternity care. | partially verified medium | SRC-017SRC-010 |
| EC-016 | Audited financials, revenue, margins, cap table, customer economics, contracts, compensation, insurance, and full legal records are not publicly verifiable. | not publicly verifiable high | SRC-001 |
Disclaimer
This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.